← Back to Clinical Trials
Recruiting NCT03312556

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Supine Hypertension
Sponsor Vanderbilt University Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 12
Sex ALL
Min Age 18 Years
Max Age 85 Years
Start Date 2017-09-21
Completion 2026-09-21
Interventions
continuous positive airway pressure (CPAP)Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

Eligibility Criteria

Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE SUPINE HYPERTENSION TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}